US OptionsDetailed Quotes

CSTL250117P40000

Watchlist

10.69
0.000.00%

15min DelayTrading Jan 6 12:23 ET

0.00High0.00Low

Castle Biosciences Stock Discussion

Stock_Drift

Oct 20, 2024 04:18

$Castle Biosciences (CSTL.US)$

Teddy123

Sep 29, 2024 21:15

New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients w

$Castle Biosciences (CSTL.US)$
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma | CSTL Stock News

Trytosaveabit

May 29, 2024 15:33

Nice!

$Castle Biosciences (CSTL.US)$ New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis 1 MINUTE AGO, 4:30 PM EDT VIA BUSINESSWIRE

Moomoo AI

Mar 17, 2024 08:44

Despite impressive revenue growth, the high P/S ratio and average growth expectations make the share price seem overvalued. Predicted future revenues may not support this positive sentiment, risking shareholders' investments and potential investors paying a premium.

More Unpleasant Surprises Could Be In Store For Castle Biosciences, Inc.'s (NASDAQ:CSTL) Shares After Tumbling 25%

Moomoo AI

Mar 3, 2024 07:37

Castle Biosciences' progress over the last year is impressive, and it is well-positioned to raise more cash for growth with minimal dilution or borrowing. Its cash burn situation is not risky due to revenue growth and cash burn reduction.

Here's Why We're Not At All Concerned With Castle Biosciences' (NASDAQ:CSTL) Cash Burn Situation

Moomoo AI

Jan 27, 2024 08:08

Investors are confident in Castle Biosciences' future growth despite its high P/S ratio. The strong future revenue growth justifies the high P/S ratio, making a significant share price drop unlikely.

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Moomoo AI

Jan 7, 2024 19:18

Derek Maetzold, president and CEO of Castle Biosciences, sees the robust revenue and test volume growth as a testament to their successful execution of growth initiatives. He is optimistic about the sustainability of this growth and momentum into 2024.

Press Release: Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results

Trytosaveabit

Oct 18, 2023 15:36

On watch

$Castle Biosciences (CSTL.US)$ Keeping a close eye to see what comes out of this? (. New Data Highlights Clinical Utility and Performance of Castle Biosciences' Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference
Businesswire· 4 mins ago

Weight-loss drugmakers report strong earnings: Boon or bane?

Moomoo AI

Oct 8, 2023 09:18

The insider's willingness to buy shares above the current price suggests their confidence in the company's future and indicates that they viewed the stock as good value, even at a higher price.

Positive Signs As Multiple Insiders Buy Castle Biosciences Stock

Trytosaveabit

Oct 5, 2023 06:03

NEWS!

$Castle Biosciences (CSTL.US)$ DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma

No comment yet